Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS) (LAPS)
Primary Purpose
Liver Tumors
Status
Unknown status
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
VLS ablation/portal ligation/hepatectomy
Sponsored by
About this trial
This is an interventional treatment trial for Liver Tumors
Eligibility Criteria
Inclusion Criteria:
- Patients aged between 18 and 70 years (M and F)
- Liver tumors that interests the right hepatic lobe (segments 4,5,6,7,8) with possible involvement of the caudate lobe (segment 1) or bilobar disease with less than 3 lesions in the left lateral lobe without vascular involvement and amenable to surgically resectable or ablation in the Step1.
- Absence of extrahepatic disease
- Normal hepatic function (total bilirubin <3 mg / dL)
- Performance status: ECOG 0
- In case of liver cirrhosis MELD score <9
- Patients without prior chemotherapy or with previous chemotherapy but with response disease
- Patients who give their consent to the intervention
Exclusion Criteria:
- CT Evidence of involvement of the major vessels in the future remnant liver
- Presence of more than 3 nodules in the left lateral lobe
- Presence of extrahepatic disease
- Severe hepatic impairment
- Age> 70 years
- Previous liver surgery (prior liver resections)
- Patient receiving chemotherapy with documented disease progression
Sites / Locations
- Chirurgia Epatobiliare e Trapianto Epatico - Azienda Ospedaliera di PadovaRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
VLS ablation/portal ligation/hepatectomy
Arm Description
Step1: exploratory laparoscopy to exclude extrahepatic disease right portal vein ligation if surgically feasible RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe) radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1 Step 2: only if FRL/body weight > 0.5 - laparoscopic/laparotomic right trisectionectomy
Outcomes
Primary Outcome Measures
Percentage of R0 resections
Percentage of operations in which a complete oncological radicality (R0) is achived
Secondary Outcome Measures
Perioperative mortality (3 months)
Percentage of perioperative mortality (3 months)
Perioperative complication (Clavien Classification)
Percentage of perioperative complication described using Clavien Dindo Classification
Time to progression
Overall survival
Overall survival at 12 and 24 months after surgery
disease free survival
hepatic diesease free survival
Full Information
NCT ID
NCT02184182
First Posted
June 23, 2014
Last Updated
July 8, 2014
Sponsor
Azienda Ospedaliera di Padova
1. Study Identification
Unique Protocol Identification Number
NCT02184182
Brief Title
Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS)
Acronym
LAPS
Official Title
Liver Resection After Portal Vein Ligation / Embolization and Transection Plane Devascularization With Radio Frequency / Microwave: Pilot Study on Primary and Secondary Liver Tumors
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Unknown status
Study Start Date
June 2014 (undefined)
Primary Completion Date
June 2016 (Anticipated)
Study Completion Date
June 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda Ospedaliera di Padova
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
One of the limiting factors in the execution of a liver resection, in particular an extended liver resection, it's represented by the future remnant liver (FRL) after hepatic surgery. In cases of normal organ function an FRL of 25% is considered sufficient. In case of impaired hepatic function or a history of chemotherapy, it is considered safe if at least of 40%.
Many strategies have been developed and proposed to increase the resectability in patients undergoing major liver resections.
One of these is a new two-stage technique proposed recently by a group of German surgeons. This approach consists in the ligation of the right portal vein associated with resection of the liver along the falciform ligament (step 1). Step 2, after a period of 9 days (median - 5-25 days), after a volumetric CT to ensure an adeguate hypertrophy of the left lateral lobe due to the combination of right portal occlusion and segment 4 devascularization, the patient undergo a right trisectionectomy. The hypertrophy of the left lateral lobe is shown to be of 74%, higher than any other techniques of ligation or portal embolizatiol proposed in the literature.
On the basis of the clinical experiences reported the investigators designed a new protocol of two-stage hepatic resection for the treatment of primary or secondary tumors of the right lobe. Step1: laparoscopic radio frequency / microwave ablation of the future transection plane between segment 4 and left lateral lobe and surgical ligation or embolization of the right portal vein. The ablation has the purpose to devascularize the segment 4 and has the same significance of the resection of the liver along the falciform ligament described by the Regensburg group.
Step2: After a period of time of 9 ± 2 days, following a volumetric CT showing an adequate liver volume gain (ratio FRL / patient body weight> 0.5), the patient undergo the second-stage surgery: laparoscopic/ laparotomic right trisectionectomy.
Detailed Description
In patients with primary or metastatic liver tumors, the only potentially curative therapeutic option is represented by hepatic resection. Nowdays extended resections can be performed with acceptable morbidity and mortality. There is no unanimous definition on the criteria of resectability and the ability to perform a more or less extensive liver resection is deferred to the expertise of the center and the surgical team. The investigators will consider a tumor resectable if the surgical procedure does not damage vital structures, the normal function of the organ is preserved and and the tumor is completely removed (R0 resection). One of the limiting factors in the execution of a liver resection, in particular if it is extended, it's represented by the future remnant liver (FRL) after hepatic resection. In cases of normal organ function an FRL of 25% is considered sufficient. In case of impaired hepatic function or a history of chemotherapy, it is considered safe if at least of 40%.
Many methods have been developed and proposed to increase the resectability in patients undergoing major liver resections. In case of bilobar tumor, a two-step approach (two-stage hepatectomy)have been proposed. This procedure implies that one of the two lobes is initially freed of disease by tumor resection or ablation. After achieving an adequate compensatory hypertrophy of the lobe freed by the tumor (usually 4-6 weeks),a contralateral liver resection can be done to treat the remnant tumor.
To increase the FRL another approach is to occlude the portal branches towards one of liver lobes. This can be done with a surgical ligation (laparotomy or laparoscopy) or radiologically, using portal embolization. The technique allows to increase from 10% to 46% of the FRL with the possibility of obtaining a resection R-0 in 70-100% of cases. It is unclear whether there is any difference between the methods of portal occlusion (ligation vs embolization). To further increase hypertrophy after portal occlusion in liver tumors occupying the right liver, some researchers proposed to embolize the portal branches of segment 4th together with the right portal vein.
The group of Regensburg has introduced a new technique in two stages for tumors of the right lobe, which combines the methods mentioned above. This two-stage approach consists in the ligation of the right portal vein associated with resection of the liver along the falciform ligament (step 1). Step 2, after a period of 9 days (median - 5-25 days), after a volumetric CT to ensure an adeguate hypertrophy of the left lateral lobe, the patient undergo a right trisectionectomy. The hypertrophy of the left lateral lobe is shown to be of 74%, higher than any other techniques of ligation or portal embolizatiol proposed in the literature.
The rationale of this technique is the complete portal devascularization of the right lobe plus segment 4 that produce a greater stimulus to hypertrophy of the left lateral segments. This occurs in less time than other methods above described and allows to reduce the timeframe between the two steps and minimizes the risk of interprocedural progression of the underlying disease (incidence of drop outs in the two-stage hepatectomy of 20% for progression disease).
The morbidity of this two-stage approach was 44% (complications of Clavien grade III and IV) that mimics the data reported in the literature for extended hepatic resections (20-50%). The 12%mortality rate was similar to one described by Lang et al for left trisegmentectomies.
On the basis of the clinical experiences reported the investigators designed a new protocol of two-stage hepatic resection for the treatment of primary or secondary tumors of the right lobe. Step1: laparoscopic radio frequency / microwave ablation of the future transection plane between segment 4 and left lateral lobe and surgical ligation or embolization of the right portal vein. The ablation has the purpose to devascularize the segment 4 and has the same significance of the resection of the liver along the falciform ligament described by the Regensburg group.
Step2: After a period of time of 9 ± 2 days, following a volumetric CT showing an adequate liver volume gain (ratio FRL / patient body weight> 0.5), the patient undergo the second-stage surgery: laparoscopic/ laparotomic right trisectionectomy
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Tumors
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
VLS ablation/portal ligation/hepatectomy
Arm Type
Experimental
Arm Description
Step1:
exploratory laparoscopy to exclude extrahepatic disease
right portal vein ligation if surgically feasible
RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)
radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1
Step 2: only if FRL/body weight > 0.5
- laparoscopic/laparotomic right trisectionectomy
Intervention Type
Procedure
Intervention Name(s)
VLS ablation/portal ligation/hepatectomy
Other Intervention Name(s)
VLS Ablation & Portal Vein Ligation for Staged Hepatectomy
Intervention Description
Step1:
exploratory laparoscopy to exclude extrahepatic disease
right portal vein ligation if surgically feasible
RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)
radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible
CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1
Step 2: only if FRL/body weight > 0.5
- laparoscopic/laparotomic right trisectionectomy
Primary Outcome Measure Information:
Title
Percentage of R0 resections
Description
Percentage of operations in which a complete oncological radicality (R0) is achived
Time Frame
30days after Step2
Secondary Outcome Measure Information:
Title
Perioperative mortality (3 months)
Description
Percentage of perioperative mortality (3 months)
Time Frame
3 moths
Title
Perioperative complication (Clavien Classification)
Description
Percentage of perioperative complication described using Clavien Dindo Classification
Time Frame
1 month
Title
Time to progression
Time Frame
12 months
Title
Overall survival
Description
Overall survival at 12 and 24 months after surgery
Time Frame
12 and 24 months
Title
disease free survival
Time Frame
12 months
Title
hepatic diesease free survival
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients aged between 18 and 70 years (M and F)
Liver tumors that interests the right hepatic lobe (segments 4,5,6,7,8) with possible involvement of the caudate lobe (segment 1) or bilobar disease with less than 3 lesions in the left lateral lobe without vascular involvement and amenable to surgically resectable or ablation in the Step1.
Absence of extrahepatic disease
Normal hepatic function (total bilirubin <3 mg / dL)
Performance status: ECOG 0
In case of liver cirrhosis MELD score <9
Patients without prior chemotherapy or with previous chemotherapy but with response disease
Patients who give their consent to the intervention
Exclusion Criteria:
CT Evidence of involvement of the major vessels in the future remnant liver
Presence of more than 3 nodules in the left lateral lobe
Presence of extrahepatic disease
Severe hepatic impairment
Age> 70 years
Previous liver surgery (prior liver resections)
Patient receiving chemotherapy with documented disease progression
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Umberto Cillo, MD, PhD
Phone
+390498211846
Email
cillo@unipd.it
First Name & Middle Initial & Last Name or Official Title & Degree
Enrico Gringeri, MD, PHD
Phone
+390498211846
Email
enrico.gringeri@unipd.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Umberto Cillo, MD PhD
Organizational Affiliation
Azienda Ospedaliera di Padova
Official's Role
Study Chair
Facility Information:
Facility Name
Chirurgia Epatobiliare e Trapianto Epatico - Azienda Ospedaliera di Padova
City
Padova
ZIP/Postal Code
35100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Umberto Cillo
Phone
+390498211846
Email
cillo@unipd.it
First Name & Middle Initial & Last Name & Degree
Enrico Gringeri
Phone
+390498211846
Email
enrico.gringeri@unipd.it
First Name & Middle Initial & Last Name & Degree
Umberto Cillo
First Name & Middle Initial & Last Name & Degree
Enrico Gringeri
First Name & Middle Initial & Last Name & Degree
Domenico Bassi
First Name & Middle Initial & Last Name & Degree
Riccardo Boetto
First Name & Middle Initial & Last Name & Degree
Francesco Enrico D'Amico
First Name & Middle Initial & Last Name & Degree
Marina Polacco
12. IPD Sharing Statement
Citations:
PubMed Identifier
22330038
Citation
Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, Horbelt R, Kroemer A, Loss M, Rummele P, Scherer MN, Padberg W, Konigsrainer A, Lang H, Obed A, Schlitt HJ. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012 Mar;255(3):405-14. doi: 10.1097/SLA.0b013e31824856f5.
Results Reference
background
PubMed Identifier
16931303
Citation
Lang H, Sotiropoulos GC, Brokalaki EI, Radtke A, Frilling A, Molmenti EP, Malago M, Broelsch CE. Left hepatic trisectionectomy for hepatobiliary malignancies. J Am Coll Surg. 2006 Sep;203(3):311-21. doi: 10.1016/j.jamcollsurg.2006.05.290. Epub 2006 Jul 13.
Results Reference
background
PubMed Identifier
15570209
Citation
Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51. doi: 10.1097/01.sla.0000145965.86383.89.
Results Reference
background
PubMed Identifier
12560779
Citation
Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, Denys A, Sauvanet A. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003 Feb;237(2):208-17. doi: 10.1097/01.SLA.0000048447.16651.7B.
Results Reference
background
PubMed Identifier
1466616
Citation
Tartter PI. The association of perioperative blood transfusion with colorectal cancer recurrence. Ann Surg. 1992 Dec;216(6):633-8. doi: 10.1097/00000658-199212000-00004.
Results Reference
background
PubMed Identifier
24151380
Citation
Donati M, Stavrou GA, Oldhafer KJ. Current position of ALPPS in the surgical landscape of CRLM treatment proposals. World J Gastroenterol. 2013 Oct 21;19(39):6548-54. doi: 10.3748/wjg.v19.i39.6548.
Results Reference
background
PubMed Identifier
15622001
Citation
Lang H, Sotiropoulos GC, Fruhauf NR, Domland M, Paul A, Kind EM, Malago M, Broelsch CE. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg. 2005 Jan;241(1):134-43. doi: 10.1097/01.sla.0000149426.08580.a1.
Results Reference
background
PubMed Identifier
18806869
Citation
Are C, Iacovitti S, Prete F, Crafa FM. Feasibility of laparoscopic portal vein ligation prior to major hepatectomy. HPB (Oxford). 2008;10(4):229-33. doi: 10.1080/13651820802175261.
Results Reference
background
PubMed Identifier
22045448
Citation
de Santibanes E, Alvarez FA, Ardiles V. How to avoid postoperative liver failure: a novel method. World J Surg. 2012 Jan;36(1):125-8. doi: 10.1007/s00268-011-1331-0.
Results Reference
background
PubMed Identifier
23483283
Citation
van Lienden KP, Hoekstra LT, Bennink RJ, van Gulik TM. Intrahepatic left to right portoportal venous collateral vascular formation in patients undergoing right portal vein ligation. Cardiovasc Intervent Radiol. 2013 Dec;36(6):1572-1579. doi: 10.1007/s00270-013-0591-5. Epub 2013 Mar 13.
Results Reference
background
Links:
URL
http://www.fegatochirurgia.com
Description
Online resource of Chirurgia Epatobiliare e Trapianto Epatico, Università degli Studi di Padova
Learn more about this trial
Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS)
We'll reach out to this number within 24 hrs